BACKGROUND: Previous studies suggest that heart failure (HF) is an independent risk factor for cognitive decline. A better understanding of the relationship between HF, cognitive status, and cognitive decline in a communitybased sample may help clinicians understand disease risk. OBJECTIVE: To examine whether persons with HF have a higher prevalence of cognitive impairment and whether persons developing HF have more rapid cognitive decline. DESIGN: This observational cohort study of American adults in the Atherosclerosis Risk in Communities (ARIC) study has two components: cross-sectional analysis examining the association between prevalent HF and cognition using multinomial logistic regression, and change over time analysis detailing the association between incident HF and change in cognition over 15 years. PARTICIPANTS: Among visit 5 (2011-2013) participants (median age 75 years), 6495 had neurocognitive information available for cross-sectional analysis. Change over time analysis examined the 5414 participants who had cognitive scores and no prevalent HF at visit 4 (1996-1998). MEASUREMENTS: The primary outcome was cognitive status, classified as normal, mild cognitive impairment [MCI], and dementia on the basis of standardized cognitive tests (delayed word recall, word fluency, and digit symbol substitution). Cognitive change was examined over a 15-year period. Control variables included socio-demographic, vascular, and smoking/drinking measures. RESULTS: At visit 5, participants with HF had a higher prevalence of dementia (adjusted relative risk ratio CONCLUSION: HF is associated with neurocognitive dysfunction and decline independent of other co-morbid conditions. Further study is needed to determine the underlying pathophysiology.
INTRODUCTION
Over five million Americans suffer from heart failure (HF). 1 Approximately 25-50% of patients with HF are estimated to have cognitive impairment, commonly reporting deficits in attention, reduced executive function, slowed processing speed, and memory loss. [2] [3] [4] Mild deficits can be classified as mild cognitive impairment (MCI), while the American Psychiatric Association defines dementia as a multidomain impairment in cognitive ability that interferes with everyday activities. 5 Cerebral hypo-perfusion due to decreased cardiac output and HF-related cardioembolic stroke may be mechanisms for the reported association of HF with cognitive impairment. 6, 7 Atherosclerotic vascular disease, whether from the cumulative exposure to cardiovascular risk factors (elevated glucose and blood pressure) or subclinical atherosclerosis, affects cognitive function and is often related to HF. [8] [9] [10] [11] [12] [13] [14] [15] Furthermore, alterations in circulatory hormones due to a failing heart or medication side effects may also lead to HF-related cognitive impairment. [16] [17] [18] Given that the risk factors for atherosclerosis, HF, and stroke (such as hypertension, diabetes, and smoking) are intertwined and overlapping, it is difficult to analyze the root cause of this HF-cognition association. Compounding this low left ventricular ejection fraction (EF) may be associated with worse cognitive performance, particularly in the presence of lower mean arterial pressure and the decompensated HF state. [19] [20] [21] The Atherosclerosis Risk in Communities (ARIC) study cohort provides an opportunity to elucidate the association between HF and cognitive dysfunction. Our study examines whether those with HF have a higher prevalence of dementia or MCI compared to those without HF. To bolster our assessment and identify more subtle changes in mental status, we also investigate the association between incident HF and change in cognitive function over time.
METHODS
This study uses multivariate regression to assess the relationship between HF and neurocognitive status in older adults through two analyses: (1) a cross-sectional analysis examining the association of HF with a categorical measure of cognition at a single point in time and (2) the association between onset of HF and the change in a continuous measure of cognition over a 15-year period.
Study Population: The ARIC Study
The ARIC study is a biracial cohort of 15,792 men and women, 45-64 years of age in 1987-1989, selected through population sampling from: Jackson, Mississippi; Forsyth County, North Carolina; suburbs of Minneapolis, Minnesota; and Washington County, Maryland. The ARIC study provides longitudinal data on risk factors and outcomes associated with atherosclerosis. Incident HF, coronary heart disease, and stroke were determined from annual follow-up phone interviews with cohort participants and review of hospitalization records. Risk factors were measured at in-person examinations. Neurocognitive information from the two most recent in-person examinations, visit 5 (2011-2013) and visit 4 (1996-1998), was used for this analysis. Only blacks were enrolled in Jackson, and extremely few blacks were enrolled in Minneapolis and Washington County. We therefore included only the majority race at each site except for Forsyth County, which included both White and Black participants. This represents standard protocol for the ARIC study. 22 
Study Sample
Of the estimated 10,036 cohort members alive in 2011, 6538 individuals participated in visit 5 (2011-2013) . Information on neurocognitive status was available for 6495 participants, who comprise the study sample for the cross-sectional analysis. For the analysis of change in neurocognitive status over time, 5414 participants who had cognition scores from both visit 4 and visit 5 and no indication of prevalent HF at visit 4 (1996-1998) were examined.
Outcomes
In our cross-sectional analysis, visit 5 participants were classified as having normal cognition, MCI, or dementia. Classification was based on a computer-derived algorithm with physician review. The computer algorithm combined data from multiple domains including scoring on standardized assessments of delayed word recall (DWR), word fluency test (WFT), and digit symbol substitution test (DSST). Memory, executive functioning, and attention were similarly analyzed, as were data reflecting orientation, judgment, and personal care. A final component assessed functioning in everyday life as reported by participant and, when indicated, a knowledgeable informant using the Clinical Dementia Rating interview. Physician reviewers adjudicated the computer-derived algorithm to ensure appropriate neurocognitive designation. This evaluation has been described elsewhere. 23, 24 The assessment of change in cognition over time examined only the subset of participants without prevalent HF at visit 4 ( Fig. 1) . Scores on three neurocognitive tests (DWR, WFT, DSST) were combined and standardized to visit 2 scores (1996-1998). 15 Performance on these tests was assessed at visit 4 and again at visit 5 (approximately 15 years apart). 25, 26 Cognitive change for those who developed HF between visit 4 and visit 5 was compared to those who did not. A separate analysis was conducted to observe cognitive change over time involving only those participants with normal cognition at visit 4. Details regarding cognitive status assessments in ARIC have been published elsewhere. 27 
Exposure and Covariates
Prevalent HF at visit 5 was classified by having at least one of the following: an adjudicated diagnosis of HF, International Classification of Disease, 9th Revision, Clinical Modification (ICD-9-CM) discharge code of 428.X in first position not overruled by a physician, self-reported HF or self-report of HF medication with pro-BNP greater than 125 pg/mL, or subsequent self-report of HF or HF medication (defined as medications participants reported taking for the treatment of HF). Prevalent HF at visit 4, which eliminated participants from the longitudinal analysis, was identified by at least one of the following: ICD-9 discharge code 428 from prior hospitalizations; self-report of HF at visit 4; or self-reported medication for HF at visit 4. HF with preserved EF (HFpEF) was defined as EF ≥ 50%, with reduced EF (HFrEF) defined as EF < 50% based on echocardiogram at visit 5. These definitions have been validated previously. [28] [29] [30] Incident HF between visits 4 and 5, used in the longitudinal analysis, was identified by hospital heart failure-specific discharge diagnosis ICD-9 codes during that follow-up interval.
Covariates included information on demographics (age, gender, study site, education) as well as marital status, individual socioeconomic status, behaviors (drinking and smoking), and selected diagnoses (depression, diabetes, hypertension, myocardial infarction, atrial fibrillation, and stroke). A Charlson co-morbidity score was included to account for debility from other diseases. 31 Hypertension was defined as systolic blood pressure (SBP) greater than 140 mmHg, a diastolic blood pressure (DBP) greater than 90 mmHg, or if the participant reported taking anti-hypertensive medication. Participants were considered diabetic if they were taking any diabetes medication, self-reported physician diagnosis of diabetes, or had a hemoglobin A1c greater than 6.5% at a study visit. Diagnoses of prevalent stroke (CVA), coronary heart disease (CHD), atrial fibrillation (AF), and myocardial infarction (MI) were ascertained from hospital records, physicians, participants, and their families throughout follow-up using standardized interviews, questionnaires, and surveillance methods previously described elsewhere. [32] [33] [34] All covariates were ascertained at visit 5, except education, occupation, race, and gender, which were reported at visit 1. The MacArthur Scale of Subjective Social Status assessed social standing relative to peers on a scale from 1 to 10. 35 A continuous measure of depression was constructed from 12 questions representing a shorter but validated form of the CES-D depression symptoms index.
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Statistical Analysis
To assess the cross-sectional association between HF and neurocognitive status at visit 5, multinomial logistic models estimated relative risk ratios (RRR) for the three-category neurocognitive outcome variable (normal, MCI, and dementia). To assess the association between onset of HF and the change in neurocognitive status between visits 4 and 5, ordinary least squares models were used. For both the crosssectional and change over time models, dichotomous measures of HF and HF ejection fraction type (reduced versus preserved EF) were used. All models included an interaction of HF with age and controlled for age, gender, ARIC site/race, education, marital status, the McArthur scale, hypertension, diabetes, stroke, AF, CES-D score, Charlson co-morbidity score, smoking status, and drinking status.
To account for non-participation in visit 5 (estimated at nearly 40%), inverse probability of attrition weighting (IPAW) was used as a sub-analysis (online appendix). For this, the probability of non-participation was predicted as a function of complete case variables (age, gender, race, study site, education, smoking status, and occupation). Multiple imputation was used in all models to allow for a complete analysis when covariate information was not directly available. All data analyses were performed using Stata v14 (StataCorp. 2015. Stata Statistical Software: Release 14. College Station, TX: StataCorp LP). Table 1 presents clinical characteristics for participants who attended visit 5. Included cohort members had a mean age of 76 years (SD 5.3) and most were female (59%). A total of 953 (15%) individuals had prevalent HF at visit 5, of whom 38% were classified as having dementia or MCI (compared to 24% of those without HF). The sample included only 105 cases of HFrEF, 11% of those with HF, while 184 (19%) individuals with HF were missing ejection fraction data. Compared to those with HF, those without HF (n = 5542) were more likely to be female and better educated. They were also more likely to be current drinkers. Among those with HFrEF, the average EF was 40% (SD 6.5) and only 33 had EF ≤ 35%. Those with HF had worse scores on standardized tests (DWR, WFT, DSST) at visit 5 compared to those without HF even when comparing only those with a diagnosis of dementia or MCI to each other (online appendix). Heart Failure and Cognitive Impairment at Visit 5 Figure 2 shows the multivariate-adjusted prevalence of dementia, MCI, and normal cognition for those with and without HF. Error bars display 95% confidence intervals for the differences compared to persons without HF. Although small sample size limits the analysis in those with HFrEF, cognition was nominally worse for participants with both HFpEF and HFrEF as compared to those without HF (online appendix).
RESULTS
Incident Heart Failure and Change in Cognition Over Time Table 3 displays the difference in the adjusted change in neurocognitive scores between visit 4 and visit 5 for those who developed HF (n = 796) during that period. We observed a significantly greater cognitive decline among persons who developed HF over the 15-year period (mean standardized z score of − 0.50 at visit 4 to − 1.02 at visit 5) compared to those who did not develop HF (mean score of 0.24 at visit 4 to − 0.20 at visit 5), with an adjusted difference of − 0.07, (95% CI − 0.13, − 0.01). This difference is interpreted as a 15-year change in standard deviation units (SDU) for those with HF as compared to those without. This change, when compared to normal aging, represents an estimated additional 1.5 years of cognitive decline. 38, 39 When analyzing change by HF type, the magnitude and direction of neurocognitive decline was similar with limited power to detect differences among those with HFrEF due to small sample size (online appendix). A post hoc analysis examining only those participants with normal cognition at visit 4 revealed that participants who developed incident HF between visits 4 and 5 had a greater decline in cognition (mean standardized z score of − 0.06) compared to those who did not develop HF (online appendix). This table shows the adjusted change in mean standardized z score on three well-studied neurocognitive tests (delayed word recall, digit symbol substitution, and word fluency). Scores were combined and standardized to visit 2 scores (1990) (1991) (1992) . This difference is interpreted as a 15-year change in standard deviation units (SDU) for those with HF as compared to those without N = 5414; All models centered at mean age. Models imputed missing covariates using multiple imputation (see Table 1 ) HF heart failure *Controlled for age, gender, site/race † Controlled for age, gender, site/race, 3-category smoking status, 3-category drinking status, 3-level education, 3-level marital status, McArthur SES scale, Charlson co-morbidity, hypertension, CHD, diabetes, atrial fibrillation, stroke Fig. 2 Predicted Proportion of those with and without heart failure to have dementia, mild cognitive impairment, or normal cognition. This figure describes the predicted prevalence (PP) of dementia, mild cognitive impairment (MCI), or normal cognition at visit 5 for those participants who developed heart failure compared to those who did not. Error bars represent the 95% confidence interval in reference to those without heart failure. *p < 0.05 compared to no HF. HF heart failure, MCI mild cognitive impairment. All models control for age, gender, ARIC site/race, education, marital status, McArthur Financial SES ladder, hypertension, diabetes, stroke, atrial fibrillation, CES-D score Charlson comorbity score, smoking status, and drinking status. Models imputed missing covariates using multiple imputation (see Table 1 ) (M = 50).
Additional analyses were conducted to examine potential effect measure modification of selected diseases, including AF, CHD, hypertension, and stroke, on the association of HF with change in cognitive status. No significant interaction was identified between these diagnoses and cognitive impairment in any HF group.
DISCUSSION
Heart failure is associated with an increased prevalence of dementia and mild cognitive impairment independent of conventional risk factors for either diagnosis. Similarly, those participants who developed incident HF showed greater cognitive decline over the same period as compared to those who did not develop HF. Given that this study controls for disease states proposed to contribute to cognitive dysfunction in the HF population (such as stroke, hypertension, diabetes, and depression), these findings suggest that HF itself may directly predispose individuals to a range of cognitive impairments.
The mechanism of this association is currently unknown and cannot be explained purely on the basis of decreased EF, as those with HFrEF showed similar results to those with HFpEF in both the cross-sectional and the change over time analyses. The relationship between EF and cognitive function has been described as nonlinear, with a steeper association between EF and decreased cognition at lower levels of EF than at higher levels; 20, 40 however, our small sample of HFrEF participants limits our analysis of this relationship, especially since only 3.5% had LVEF ≤ 35%. Proposed pathways connecting HF to cognitive decline include cerebral atrophy from hypo-perfusion, infarction due to decreased blood flow, subclinical cardioembolic phenomena, and an association between natriuretic peptides and the deposition of amyloid plaques in the brain. 16, 17, 41, 42 Other possible causes include the interplay between decreased cardiac output and previously described co-morbidities including microvascular damage from diabetes, vascular damage from hypertension, and arterial disease. 2, 43, 44 Finally, the association might be noncausal, e.g., the result of confounding by the use of certain medications. The relationship between HF and cognitive decline is possibly bidirectional as those with HF may suffer cognitive decline as shown in our study; however, baseline poor cognition may lead to poor medication adherence for chronic diseases such as HTN and CHD further pre-disposing them to HF. 45 Previous studies have described a similar relationship between HF and cognitive impairment. Jefferson et al. examined a small cohort of elderly individuals (n = 72) and found that those with worse executive functioning were more likely to have low cardiac output. 19 When examining a cohort of decompensated HF patients (n = 20) compared to healthy controls, Kindermann and colleagues noted worse cognition in those with HF. 21 Gottesman and colleagues examined 234 individuals with coronary arterial disease and found that those with lower EF had lower global functioning scores and worsened motor function. 20 A systematic review published in 2007 by Vogels et al. pooled analyses of case-control studies examining almost 3000 patients with HF. This analysis showed that patients with HF had increased prevalence of cognitive impairment (odds ratio 1.62, 95% CI 1.48-1.79) than those without HF. 17 All these studies suggest a strong crosssectional relationship between HF and cognitive impairment, though the studies varied in their control for cardiovascular risk factors and other potential confounders.
Although prior longitudinal studies have demonstrated the relationship between more pronounced cognitive decline and heart failure, our multi-center ARIC cohort study is unique in its combination of size, detailing of cognitive status, and its lengthy follow-up of over 15 years. 46 All elderly participants in this large cohort were originally recruited at home and assessed in the ARIC field centers. Thus, this analysis refers to a group of individuals most of whom were healthy enough to attend nearly daylong in-person visits. Also, because of our unique outpatient setting, the observed association between HF and cognitive impairment is less likely to be confounded by delirium or situational depression, which was noted in studies consisting primarily of hospitalized patients. 17 Additionally, our study's neuropsychological assessment included a wide range of cognitive abilities: executive functioning, spatial reasoning, and ability to perform activities of daily living. The extensive neuropsychological evaluations undertaken in this analysis and examination of an elderly population from the community is only matched by European studies including the Rotterdam Study and Three-City Study. Furthermore, ARIC includes a more racially diverse population than these other analyses. 47, 48 Our study details a clear association between HF and MCI as well as dementia, which is less well described in current literature.
Several limitations pertain to this study. Importantly, although we examine a wider range of health and disease than is possible in hospital-based studies, due to the physical and temporal requirements of the comprehensive in-person examination, ARIC participants who completed visit 5 were inherently healthier than those who refused or were unable to participate. This healthy-participant effect likely contributes to the low observed prevalence of dementia and limits our ability to examine the very sickest HF patients or those with severe dementia. Additionally, our analysis examines the relationship of the change in cognition over time and concurrent development of HF. While this design works to avoid confounding by factors which are stable over time in participants (such as educational or intellectual background), the data did not allow us to determine which occurred first (cognitive decline or development of HF), so causal interpretations are not possible. Prior studies have demonstrated a predisposition to develop heart failure as cognitive function declines, and it is possible that this relationship is bidirectional which may falsely strengthen the observed relationship. 27 HF medications have also been proposed to interact with or contribute to cognitive decline. Only limited information was available regarding medication usage, adherence, and temporality between visits 4 and 5, limiting inclusion of potential medication effects in our analysis. Finally, the observational nature of the study means that we cannot be sure of freedom from residual unmeasured confounding.
Despite these limitations, this analysis highlights associations between HF and neurocognitive decline that cannot be explained by known and observed risk factors. These findings can aid clinicians when caring for HF patients and ensure they are attuned to the risk of cognitive decline associated with this disease. It also provides potential areas for further analysis and therefore intervention to prevent cognitive decline, whether by improved HF treatment, increasing cardiac output, or adjusting medications.
Future studies should aim to observe changes in cognitive function occurring after HF develops, with possible neurologic imaging and more detailed examinations of disease states that may contribute to cognitive decline. Similarly, potential differences in cognitive status among those with HFrEF as compared to those with HFpEF warrant additional investigation, given a potential relationship between cardiac output and cognitive decline.
